Table 3 Comparison between groups (according to USPSTF recommendation)
Characteristics | Pre-recommendation 448 Pts. (31.5%) | Post-recommendation 977 Pts. (68.5%) | P-value |
|---|---|---|---|
Age, median [IQR] | 74 [68–80] | 71 [65–77] | |
Age at diagnosis, mean [range] | 68.2 [41–96] | 68.8 [40–93] | 0.258 |
Age categories, n (%) | <.0001 | ||
- < 50 years | 1 (0.2%) | 7 (0.7%) | |
- 50–74 years | 234 (52.2%) | 627 (64.2%) | |
- ≥75 years | 213 (47.6%) | 343 (35.1%) | |
PSA (ng/ml), median [IQR] | 6.4 [4.9–10.1] | 8 [5.7–12.9] | 0.0007 |
PSA categories, n (%) | <.0001 | ||
- ≤4 | 48 (10.7%) | 65 (6.6%) | |
- 4.01–10 | 287 (64.1%) | 548 (56.1%) | |
- 10.01–20 | 76 (16.9%) | 217 (22.2%) | |
- > 20 | 37 (8.3%) | 147 (15.1%) | |
Prostate volume (ml3), median [IQR] | 34.9 [26–46.2] | 37.2 [27.1–51] | 0.126 |
PSA density (ng/ml/ml3), median [IQR] | 0.19 [0.13–0.33] | 0.22 [0.14–0.39] | 0.132 |
Gleason score | <.0001 | ||
- Gleason 6 | 240 (53.5%) | 326 (33.4%) | |
- Gleason 7 | 127 (28.4%) | 346 (35.4%) | |
- Gleason 8–10 | 81 (18.1%) | 305 (31.2%) | |
Clinical stage | <. 0001 | ||
- T1-2a | 301 (67.1%) | 558 (57.1%) | |
- T2b | 107 (23.9%) | 248 (25.4%) | |
- T2c-3a | 40 (9%) | 171 (17.5%) | |
D’Amico risk classification | <. 0001 | ||
Low | 202 (45.1%) | 275 (28.1%) | |
Intermediate | 147 (32.8%) | 356 (36.4%) | |
High | 99 (22.1%) | 346 (35.5%) | |